Amgen Expects to Complete Acquisition of Horizon Therapeutics in First Half of 2023

On February 6, Amgen announced its financial results for the fourth quarter and full year of 2022. In the fourth quarter of 2022, the company's total revenue reached $6.8 billion, with earnings per share under Generally Accepted Accounting Principles (GAAP) at $3.00; for the full year of 2022, total revenue reached $26.3 billion, with GAAP earnings per share at $12.11. Amgen stated that it expects to complete the acquisition of Horizon Therapeutics plc in the first half of this year.